Upgrade to SI Premium - Free Trial

Actinium Pharma (ATNM)

1.07 +0.06 (5.94%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/3/26)

Latest Headlines

Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer June 3, 2026 8:02 AM - StreetInsider Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer June 3, 2026 8:00 AM - PR NewsWire Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros June 3, 2026 7:25 AM - PR NewsWire Actinium Pharmaceuticals names Steffen Heeger as chief medical officer June 1, 2026 8:01 AM - StreetInsider Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development June 1, 2026 8:00 AM - PR NewsWire Actinium Pharmaceuticals presents CAR optimization data at SNMMI 2026 June 1, 2026 7:01 AM - StreetInsider Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates June 1, 2026 7:00 AM - PR NewsWire Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs May 29, 2026 5:31 PM - PR NewsWire Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice May 29, 2026 5:30 PM - PR NewsWire Form 8-K Actinium Pharmaceuticals For: May 27 May 29, 2026 5:11 PM - SEC Filing Form 10-Q Actinium Pharmaceuticals For: Mar 31 May 8, 2026 5:01 PM - SEC Filing Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization May 6, 2026 8:00 AM - PR NewsWire Actinium reports ATNM-400 cancer therapy data at AACR meeting April 22, 2026 7:01 AM - StreetInsider Actinium presents data on Actimab-A mechanism at cancer research meeting April 22, 2026 7:01 AM - StreetInsider Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting April 22, 2026 7:01 AM - PR NewsWire Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer April 22, 2026 7:01 AM - PR NewsWire Actinium Pharmaceuticals to present data on ATNM-400 and Actimab-A at AACR April 6, 2026 7:30 AM - StreetInsider Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting April 6, 2026 7:30 AM - PR NewsWire Form 10-K Actinium Pharmaceuticals For: Dec 31 March 30, 2026 5:51 PM - SEC Filing Form 8-K/A Actinium Pharmaceuticals For: Nov 26 March 26, 2026 5:00 PM - SEC Filing Full Article List